|
Markt geschlossen -
Japan Exchange
07:30:00 13.02.2026
|
% 5 Tage
|
Veränd. 1. Jan.
|
|
10.585,00 JPY
|
+7,23 %
|
 |
+13,28 %
|
+19,29 %
|
|
13.02. |
Otsuka Holdings Co., Ltd. Announces Dividend for the Fiscal Year Ended December 31, 2025, Payable on March 30, 2026
| | |
13.02. |
Otsuka Holdings Co., Ltd. Provides Earnings Guidance for the Second Quarter (Year to Date) and for the Year Ending December 31, 2026
| | |
13.02. |
Otsuka Holdings Co., Ltd. Provides Dividend Guidance for the Second Quarter of Fiscal 2026 and Year Ending December 31, 2026
| | |
13.02. |
Otsuka Holdings Co., Ltd. authorizes a Buyback Plan.
| | |
13.02. |
Otsuka Holdings Co., Ltd. announces an Equity Buyback for 7,000,000 shares, representing 1.33% for ¥50,000 million.
| | |
13.02. |
Japan Stocks End Week in Red As BOJ Hawk Flags Near-Term Rate Rise
| | |
13.02. |
Otsuka Holdings Co Ltd to buy back up to 1.33% of own shares worth 50 billion yen
| | |
13.02. |
Otsuka's Profit Climbs 20% in 2025
| | |
04.02. |
Biodexa announces exclusive license of Otsuka's OPB-171775, a potent phase 1 ready molecular glue for GIST
| | |
04.02. |
HBM Holdings Limited Provides Consolidated Earnings Guidance for the Year Ended December 31, 2025
| | |
02.02. |
Otsuka Corporation Provides Dividend Guidance for the Second Quarter End of Fiscal Year Ending March 31, 2026
| | |
02.02. |
Otsuka Corporation Provides Dividend Guidance for the Fiscal Year Ending March 31, 2026
| | |
27.01. |
Cms announces selection of drugs for third cycle of the Medicare drug price negotiation program
| | |
22.01. |
Vertex Pharmaceuticals Poised for Higher Valuation on Povetacicept, Cystic Fibrosis Pipeline, RBC Says
| | |
14.01. |
Otsuka Holdings Submits Commitment Letter to Obtain Science-Based Targets Validation for the Entire Otsuka Group
| | |
12.01. |
Ionis Pharmaceuticals, Inc. Provides Additional Updates on Key Milestones Expected in 2026
| | |
26.11. |
Bourse : Thales et Dassault vont créer une IA de guerre, Dell séduit au contraire de HP
| | |
26.11. |
Le marché retrouve son Mojo
| | |
26.11. |
Otsuka Wins U.S. FDA Accelerated Approval for VOYXACT
| | |
26.11. |
Otsuka Holdings Co receives FDA accelerated approval for Voyxact for proteinuria reduction in adults with primary immunoglobulin A nephropathy at risk for disease progression
| | |
25.11. |
Fda approves use of Voyxact to reduce proteinuria in primary immunoglobulin
| | |
25.11. |
US FDA approves Otsuka's drug for a type of kidney disease
| | |
14.11. |
Ema's CHMP announces positive recommendation on extension of therapeutic indications for Koselugo
| | |
10.11. |
Japanese Shares Rise as U.S. Shutdown Deal Nears
| | |
10.11. |
Otsuka Pharmaceutical, Co. Ltd. Announces Findings from 12-Month Interim Analysis of Sibeprenlimab for the Treatment of Immunoglobulin A Nephropathy in Adults
| |
Keine Ergebnisse zu dieser Suche Bitte wählen Sie Ihre Ausgabe Alle länderspezifischen Finanzinformationen
MarketScreener is also available in this country: United States.
Switch edition
Bei der aktuellen länderspezifischen Edition bleiben
| 
